市场调查报告书
商品编码
1349209
异种移植市场规模 - 按产品类型(器官保存解决方案、移植诊断、异种产品)、按应用(肾、心、肝、肺)、按最终用途 - 到 2032 年的全球预测Xenotransplantation Market Size - By Product Type (Organ Preservation Solution, Transplant Diagnostics, Xeno Products), By Application (Kidney, Heart, Liver, Lung), By End-use- Global Forecast to 2032 |
2023 年至 2032 年间,全球异种移植市场的复合年增长率将达到 8.9%。用于移植的人体器官持续短缺,迫切需要替代解决方案。异种移植,即将动物的器官或组织移植到人类身上,在这方面提供了一条有前途的途径。基因工程的进步使得基因改造猪的发展成为可能,其器官与人类免疫系统更相容。这项突破促进了异种移植的研究和投资。
领先公司之间不断增长的合作伙伴关係也支持了异种移植市场的前景。例如,2023 年 4 月,传染病诊断领域的知名人士 Karius 与异种移植领域的拓荒者 eGenesis 建立了合作关係。此次合作将重点开发专为异种移植设计的传染病诊断方法。
整个异种移植市场根据产品、应用、最终用途和地区进行分类。
在产品方面,器官保存解决方案领域从2023年到2032年将呈现8.8%的复合年增长率。随着异种移植领域探索利用动物器官进行人体移植,对有效的保存方法的需求至关重要。器官保存解决方案在运输和移植过程中维持收穫器官的活力和功能方面发挥着至关重要的作用。延长器官保质期、提高移植成功率和解决人类捐赠器官严重短缺的潜力使其在异种移植市场中被采用。
在应用方面,2023年至2032年,肺臟部分的复合年增长率将达到8.6%。肺移植仍然是终末期肺病患者的迫切需求,而合适的人体供体器官的短缺是一个持续的挑战。异种移植,涉及使用基因改造猪肺,提供了一个潜在的解决方案。扩大可用器官库、改善等待名单结果并最终挽救更多生命的承诺推动了对异种移植肺的需求不断增长。
就最终用途而言,从 2023 年到 2032 年,医院领域的复合年增长率将达到 9.1%。异种移植涉及将动物的器官或组织移植到人类体内,为接受救生手术的患者带来了希望。随着等待器官移植的患者数量不断增加,医院正在探索这种创新方法来扩大可用器官库,并支持异种移植市场收入。
从地区来看,2023年至2032年,欧洲异种移植产业的复合年增长率将达到9.1%。该大陆面临与世界其他地区类似的挑战,用于移植的人类捐赠者器官短缺。因此,医学界越来越多地探索异种移植作为可行的解决方案。不断增加的研究投资、有利的监管发展以及对推动医学科学的承诺是这项需求的驱动因素。欧洲透过异种移植积极主动地解决器官短缺问题,凸显了该地区致力于改善患者治疗效果和满足关键医疗保健需求的决心。
Global Xenotransplantation Market will witness an 8.9% CAGR between 2023 and 2032. A persistent shortage of human organs for transplantation has created a pressing need for alternative solutions. Xenotransplantation, the transplantation of organs or tissues from animals into humans, presents a promising avenue in this regard. Advancements in genetic engineering have enabled the development of genetically modified pigs, whose organs are more compatible with the human immune system. This breakthrough has bolstered research and investment in xenotransplantation.
The growing partnerships between leading companies also support the xenotransplantation market outlook. For instance, in April 2023, Karius, a prominent player in infectious disease diagnostics, entered a collaboration with eGenesis, a trailblazer in xenotransplantation. This partnership will focus on the development of infectious disease diagnostics specifically designed for xenotransplantation.
The overall Xenotransplantation Market is classified based on product, application, end-use, and region.
In terms of product, the organ preservation solution segment will demonstrate an 8.8% CAGR from 2023 to 2032. As the field of xenotransplantation explores the use of animal organs for human transplantation, the need for effective preservation methods is paramount. Organ preservation solutions play a crucial role in maintaining the viability and functionality of harvested organs during transportation and transplantation procedures. The potential to extend the shelf life of organs, improve transplant success rates, and address the critical shortage of human donor organs leads to its adoption in the xenotransplantation market.
With respect to application, the lung segment will register an 8.6% CAGR from 2023 to 2032. Lung transplantation remains a critical need for patients with end-stage lung diseases, and the shortage of suitable human donor organs is a persistent challenge. Xenotransplantation, involving the use of genetically modified pig lungs, offers a potential solution. The increasing demand for xenotransplanted lungs is driven by the promise of expanding the pool of available organs, improving waiting list outcomes, and ultimately saving more lives.
Regarding end-use, the hospitals segment will showcase a 9.1% CAGR from 2023 to 2032. Xenotransplantation, which involves transplanting organs or tissues from animals into humans, offers hope to patients undergoing life-saving procedures. With an increasing number of patients awaiting organ transplants, hospitals are exploring this innovative approach to expand the pool of available organs, supporting the xenotransplantation market revenue.
Regionally, Europe xenotransplantation industry will record a 9.1% CAGR from 2023 to 2032. The continent faces similar challenges as the rest of the world, with a shortage of human donor organs for transplantation. As a result, the medical community is increasingly exploring xenotransplantation as a viable solution. Growing investment in research, favorable regulatory developments, and a commitment to advancing medical science are driving factors in this demand. Europe's proactive approach to addressing organ shortages through xenotransplantation highlights the region's dedication to improving patient outcomes and addressing critical healthcare needs.